Axonics® announces first patient implants in canada with new recharge-free sacral neuromodulation system

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in canada with the axonics f15™, the company's newly developed, long-lived, fully recharge-free sacral neuromodulation (snm) system. the university of alberta implanted four patients this week with the axonics f15. the four patients were programmed at
AXNX Ratings Summary
AXNX Quant Ranking